Sign In
Buy CFRX
$0.0500
+0 (+0%)
At Close: Mar 04, 2024
ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modal
CFRX: Updated Financials Following 1:10 Reverse Split; Phase 3 DISRUPT Trial Underway…
08:45pm, Tuesday, 18'th Feb 2020
By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Financial Update On February 4, 2020, ContraFect (NASDAQ:CFRX) announced a one-for-ten reverse stock split. We have updated this repo
Weekly Summary Corporate dividends, name changes, new listings
08:21pm, Friday, 07'th Feb 2020
NEW YORK (AP) — Changes announced in corporate dividends Feb. 3-Fev. 7. INCREASED DIVIDENDS Activision Blizzard .41 from .37 Aflac Inc .28 from .27 Arch Coal Inc Cl A .50 from .45 Avista Corp .405 f
ContraFect Announces One-for-Ten Reverse Stock Split
12:00pm, Tuesday, 04'th Feb 2020
ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modal
ContraFect Appoints Jane E. Ambler, Ph.D. as Vice President of Clinical Microbiology
12:00pm, Monday, 03'rd Feb 2020
ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modal
ContraFect Announces Oral Presentations at the 30th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
12:00pm, Monday, 27'th Jan 2020
ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including Lysins and Amurin peptides, as new medical modal
HEXO, NIO among premarket gainers
02:21pm, Wednesday, 22'nd Jan 2020
One Stop Systems (NASDAQ:OSS) +56% reports prelim results.Genprex (NASDAQ:GNPX) +52%.Akcea Therapeutics (NASDAQ:AKCA) +14% as antisense candidate successful in mid-stage hypertriglyceridemia study.T
ContraFect to Present at 2020 ASM Biothreats
12:00pm, Wednesday, 22'nd Jan 2020
ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modal
CFRX: Phase 3 DISRUPT Trial Underway…
10:00am, Tuesday, 21'st Jan 2020
By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Business Update Phase 3 DISRUPT Trial Underway On January 10, 2020, ContraFect Corp. (NASDAQ:CFRX) announced the first patient has be
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 13.) Arvinas Inc (NASDAQ: ARVN ) Baxter Int
DDD, NVTA among premarket gainers
02:27pm, Monday, 13'th Jan 2020
Adaptimmune Therapeutics PLC (NASDAQ:ADAP) +56% as SPEAR T-cell platform delivers initial responses in four solid tumors.Verona Pharma PLC (NASDAQ:VRNA) +54% on positive ensifentrine data.Mereo BioP
ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modal
Top 5 Crowdfunding Platforms in Philippines 2018 - Fintech Singapore
12:09am, Thursday, 24'th May 2018
The emergence of crowdfunding activities in the Philippines in recent years now valued to millions has compelled the Securities and Exchange Commission (SEC) to craft rules and regulations that will
Canon EOS 5D Mark III review: Canon EOS 5D Mark III
01:46am, Tuesday, 08'th May 2012
Canon EOS 5D Mark III
